• Trump reacts to not winning the Nobel Peace…
  • Trump says mass government layoffs will be 'Democrat…
  • Oct. 10, 2025, 4:15 PM EDTBy Minyvonne Burke…
  • Are there health benefits to communal screaming?

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

California sues Trump admin. over National Guard deployment

admin - Latest News - October 5, 2025
admin
13 views 27 secs 0 Comments



California Governor Gavin Newsom said on Sunday that the state is suing President Trump over the deployment of hundreds of California National Guard troops to Oregon. It comes as the president vows to send troops to Chicago and Portland in response to protests against immigration raids. NBC News’ Maggie Vespa reports.



Source link

TAGS:
PREVIOUS
Here's the biggest news you missed this weekend
NEXT
Pilots lift off for New Mexico balloon festival
Related Post
September 23, 2025
Sept. 23, 2025, 2:00 PM EDTBy Max GaoCanadian comic Mae Martin knows their new Netflix limited series — which blends light-hearted comedic elements with the anxiety-inducing horror and thriller genres — may feel like a dramatic departure for anyone who is familiar with their stand-up routines and their semi-autobiographical show, “Feel Good.”“It’s funny because it doesn’t feel like a departure for me,” Martin, who identifies as nonbinary and uses they/them pronouns, told NBC News. “It feels thematically in the same universe as everything I do. It’s introspective, and there’s themes about processing adolescence and identity.”“Wayward,” which premieres Thursday, stars Martin as Alex Dempsey, a police officer who has just moved to the seemingly picturesque small town of Tall Pines with his pregnant wife, Laura (Sarah Gadon). During one of his first days in the city, where his wife grew up, Alex crosses paths with two students from the local academy for “troubled teens” who are desperately trying to plot their escape. As he begins investigating a series of unusual incidents, Alex suspects that Evelyn Wade (Toni Collette) — the school’s enigmatic leader who shares a troubling personal connection with Laura — might be at the center of all the town’s problems.“Alex is sort of the eyes of the audience and trying to piece it all together. It’s so seductive to be in a town that is so accepting and progressive on the surface and is offering him everything he’s always dreamed of,” Martin explained. But over the course of eight episodes, Alex, who is a transgender man, “is grappling with his moral compass and also his intense yearning to have that nuclear family and mainstream acceptance that he’s always wanted.”After Martin rose to fame internationally during the Covid-19 pandemic for co-creating the romantic dramedy series “Feel Good,” in which they played a fictionalized version of themselves, some viewers may have expected the writer to create a new project that would feel similarly autobiographical. But Martin said they have been wanting to make a show for decades set against the backdrop of the “troubled teen industry,” a term used for the broad range of controversial youth residential programs aimed at struggling teenagers.“My best friend Nicole got sent to a troubled teen institute in the States, and she was gone for about two years,” said Martin, who grew up in Toronto. “That sparked my interest in some of the shadier practices and the really strange origins of that industry, which all trace back to self-help cults in the 1970s and this really theatrical behavioral modification.”At first, Martin thought the series would be more of a classic, coming-of-age story in the vein of “Stand By Me” or “Holes.” But after hearing about their best friend’s harrowing experiences at one of those unregulated schools — where she recalled being starved, sleep deprived and forced to dig and stand in her own grave overnight — Martin could tell that a tale about troubled teens being held against their will would be much more in line with classic horror and thriller films such as “Fargo,” “Get Out” and “Rosemary’s Baby.”Over time, Martin said, they became more interested in looking “directly at how many young people are pathologized at such a young age, just for having a pretty normal reaction to a sick society.” “When you take kids who are in crisis and your reaction is punitive, you take away their opportunity to go through all the normal milestones of development, and you ascribe labels to them that really affect how they see their own potential,” they said. Mae Martin and Toni Collette in “Wayward.”Michael Gibson / NetflixMartin said they have found themselves increasingly thinking about “the state of the world that we’re passing down to young people, and about intergenerational conflict.”“As we get older, we suppress so much of our sensitivity and our critical thinking and even our empathy just in order to survive in the world,” Martin said. “So we can’t help but kind of gaslight young people out of their very correct observation that the world is insane, and that there’s a lot of hypocrisy out there.”From the outset, Martin said, they knew they wanted to play Alex. While his gender identity is only explored in passing, “a lot of his inner yearning is connected to that and how he sees himself and wants to be seen in the world,” especially as a husband and an expectant father, Martin explained.“The show’s set in 2003, and I think there wasn’t a lot of fluency around nonbinary identity then and not a lot of they/thems,” Martin noted, adding that playing a man “just made sense” to them. “Who knows where I’ll end up on that spectrum? But it felt pretty natural to me as an actor — more natural than it would’ve been to play a woman.”As the creator and co-showrunner of “Wayward,” Martin is one of the few LGBTQ writers in Hollywood who are shepherding their own mainstream projects. While they said they try not to think too much about their public profile when creating their projects, Martin said it is “scary” to be a queer creative at a time when President Donald Trump and conservatives have been actively targeting and rolling back legal protections for the queer community, especially trans and nonbinary people.Toni Collette and Joshua Close in “Wayward.”Netflix“What makes things difficult is when things are charged politically, like they are now, it makes it seem like even having a trans character or a gay character is a political statement and immediately puts your project in a niche category,” said Martin. “It’s crazy that your career can be affected by political swings like that.”Martin said they see their visibility as a prominent nonbinary comedian in the current climate as a double-edged sword. On the one hand, they want to tell stories that will reach the widest audience possible and, hopefully, in turn, create more empathy for the LGBTQ community. But at the same time, Martin said, they know that their mere existence can be seen as a kind of political statement.They said they would welcome an environment where an LGBTQ character’s identity was “just incidental,” rather than a defining feature of the project, “and the focus is actually on these hugely universal themes and storylines.”In “Wayward,” for instance, “there are nuances that are specific to the queer experience that I think queer people will pick up on and relate to, but those things are pretty relatable to anyone who’s experienced any kind of otherness,” Martin said.Martin speculated that the heightened backlash against the trans community is connected to depictions of trans people that have disproportionately focused on transphobia, bigotry and trauma. “It is a part of the trans experience, but it’s just one small part of a human experience,” they said. “The more we can have diverse characters who are flawed, funny, weird and relatable, who make mistakes, who have relationships — I think that would be more helpful.”Martin acknowledged there’s been a contraction in the output of diverse stories, but they plan to keep “sneaking subversive things” into more mainstream projects.“I’ll just keep my head down, keep inundating people with scripts, and hope to ride it out and do my part,” Martin said.Max GaoMax Gao is a freelance entertainment and sports journalist based in Toronto. He has written for NBC News, The New York Times, the Los Angeles Times, Sports Illustrated, The Daily Beast, Harper’s Bazaar, Elle, Men’s Health, Teen Vogue and W Magazine. 
October 9, 2025
Special Report: Grand jury indicts N.Y. Attorney General Letitia James
September 30, 2025
What happens when the government shuts down?
September 27, 2025
Sept. 27, 2025, 5:30 AM EDTBy Berkeley Lovelace Jr.For people who rely on certain prescription drugs, including weight loss, asthma and cancer medications, President Donald Trump’s post announcing 100% tariffs on foreign brand-name drugs offers little clarity on when — or if — medications might see price hikes. “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump said on Truth Social late Thursday. “‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”Experts say Trump’s post raises a lot of questions. Here are five major ones. What drugs will be impacted?Trump’s post doesn’t specify whether brand-name drugmakers with an existing U.S. plant would be exempt, whether that exemption would include all their products, or whether it would only be for the drugs manufactured at the U.S. site. Novo Nordisk and Eli Lilly, makers of the weight loss drugs Wegovy and Zepound, respectively, have announced plans to invest in U.S. manufacturing. But it’s unclear if their intent to invest will warrant an exemption. On Tuesday, Lilly announced plans for a $6.5 billion manufacturing facility in Houston that will produce Zepbound and its other GLP-1 drug, Mounjaro, following a recent commitment to build a $5 billion plant near Richmond, Virginia. Novo Nordisk, a Danish company, said in June it would spend $4.1 billion to construct a second GLP-1 fill-finish plant in Clayton, North Carolina.AstraZeneca, which makes the asthma drug Symbicort, also announced in July that it will invest $50 billion over the next five years to expand its research and development and manufacturing footprint in the U.S. Many other popular brand-name drugs, however, are primarily manufactured overseas, particularly in Europe, said Rena Conti, an associate professor at Boston University’s Questrom School of Business.Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (Keytruda’s manufacturing has increasingly moved to the United States in recent years, but it’s not clear if that would earn an exemption from Trump’s tariffs.)Others, including some for blood and lung cancers, as well as vaccines, are made in places like India and China, Conti said. “I think what’s most at risk here are branded products that come from China and India,” she said. The E.U. and Japan already have trade agreements in place that cover pharmaceuticals, she added, and it’s unclear whether the new tariff will supersede that. Will patients see prices increase?Only 1 in 10 of the prescriptions filled in the U.S. are for brand-name drugs; the vast majority are for generics, which are much cheaper and will not be affected by these tariffs. Whether patients see price increases will depend on how many drugmakers receive exemptions — and on whether companies choose to pass those costs on to patients at the pharmacy counter, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. ​​“Ultimately, tariffs are taxes on patients,” Kesselheim said, “and to the extent that drug companies see increases in cost due to tariffs, they will pass those costs on to patients.”Some companies may decide not to pass the costs along. So far, the 15% tariffs on imports from the E.U. haven’t translated into big price hikes for U.S. patients, Conti noted. To be sure, a 100% tariff would be far more costly for a company. Price hikes may not start right away, as drugmakers find out whether they qualify for an exemption. There also might be a lag since U.S. law prevents drugmakers from increasing the price of drugs faster than inflation.“What if you’re doing updates to the plant you currently have? What if you’re planning a facility? Do those count?” Kesselheim said. “It’s all very ambiguous.”Some patients may not notice additional price hikes at all, given how costly brand-name drugs already are in the U.S., said Arthur Caplan, the head of the Division of Medical Ethics at NYU Langone Medical Center in New York City. “I can certainly predict that some patients will immediately feel price increases that will shock them on some of these drugs,” Caplan said.Could insurers absorb the costs?Insurers and middlemen, known as pharmacy benefit managers, could try to negotiate drugmakers or absorb some of the tariff-related costs, Caplan said.It’s more likely, however, that they’d pass it on to patients in the short term, potentially in the form of a larger copay, he said.It’s not only patients with private insurance that should be worried about price hikes, Kesselheim said. Those who get their drugs covered through government health programs could also see price increases.“The government is the largest purchaser of prescription drugs in the market, through Medicare, Medicaid and the VA, so it’s really the government or government payers that are going to see the largest impact on price increases,” he said. Will tariffs spur more U.S. drug manufacturing?It’s unlikely, Kesselheim said. The decision to build a plant “is a complicated and expensive one” that requires several regulatory hurdles and years of planning.Conti noted that by the time new manufacturing plants are completed, Trump would likely be out of office.“It is somewhere between two years and five years to get new production facilities built,” she said, “and it can be in the millions of dollars depending on whether the product that you’re making is a small molecule drug or a biologic.”Even putting money back into an existing plant isn’t quick.“If you want to switch a line or retool a factory to make a product, then we’re talking about somewhere between 18 to 36 months to do that,” Conti said, “because you have to show the U.S. regulator that you can make it at this factory at scale, and the product is what it says it is, or is high quality and meets the quality standards of the U.S.”In a statement, Alex Schriver, a spokesperson for the trade group the Pharmaceutical Research and Manufacturers of America, said “most innovative medicines prescribed in America are already made in America” and companies continue to invest in the U.S.“Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Schriver said. “Medicines have historically been exempt from tariffs because they raise costs and could lead to shortages.”What about shortages?If Trump keeps his focus solely on brand-name drugs, U.S. patients are unlikely to face shortages, Kesselheim said.“Their profits are just so, so far beyond this tariff cost that they could probably be OK or raise the prices of the drugs,” he said. “They would probably not stop production as a result.”But that excludes, he added, some smaller companies who may make niche brand-name products and may not have the resources to take on the extra costs. If tariffs extend to generics, the risk is far greater, Caplan added. Unlike brand-name drugs, generic drugs are typically sold at close to the cost they’re made, he said, which makes it difficult for companies to justify the cost of building a new facility. They’d likely be forced to walk away from production or close their plants altogether.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved